A new weight-loss injection priced at ₹14,000 per month has entered the Indian market, but the country’s obesity epidemic is no small concern. With Eli Lilly’s Mounjaro launching ahead of Novo Nordisk’s Wegovy, pharmaceutical giants are competing to dominate this growing sector.
Prime Minister Narendra Modi recently highlighted the alarming rise in obesity, citing a Lancet study that predicts 440 million Indians could be obese by 2050. He also warned that one in three individuals may face severe health complications due to obesity.
The financial impact is equally concerning—India’s obesity-related costs stood at $28.95 billion (1% of GDP) in 2019, according to the Global Obesity Observatory. This burden is projected to skyrocket to $838.6 billion by 2060, consuming 2.5% of the country’s GDP.
Discussion about this post